NeuroSense Therapeutics announced its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, is available through its website (https://www.neurosense-tx.com), and provided a business update.
“During the fourth quarter, we continued to make progress in advancing our lead combination drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS) in the Phase 2b PARADIGM trial. As over 50% of the patients have been enrolled, we expect to release topline results in the second half of 2023,” stated NeuroSense’s CEO, Alon Ben-Noon.